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Patients with end-stage renal disease (ESRD) receiving
hemodialysis (HD) treatment have a markedly shortened life
expectancy in large part owing to cardiovascular disease
(CVD), not explained by established risk factors. We tested
the hypothesis that therapy with valsartan, an angiotensin
receptor blocker and amlodipine, an antioxidant calcium
channel blocker will reduce oxidative stress and the
plasma levels of asymmetric dimethylarginine (ADMA), an
endogenous inhibitor of nitric oxide synthase. We confirmed
that compared with age- and gender-matched healthy
controls, ESRD patients have excessive oxidative stress and
arginine methylation as indexed by elevated plasma levels of
oxidation products of lipids (13-hydroxyoctadecadienoic acid
(13-HODE)), thiols (oxidized:reduced glutathione, oxidized
glutathione (GSSG):GSH), proteins, and nucleic acids,
and the methylation products ADMA and symmetric
dimethylarginine (SDMA). We undertook a double blind,
crossover study of equi-antihypertensive treatment with
amlodipine and valsartan for 6 weeks each to test our
hypothesis. Both treatments significantly reduced GSSG:GSH,
8-hydroxy 2-deoxyguanosine, ADMA, and SDMA levels
and amlodipine reduced 13-HODE. We conclude that
hypertensive patients with ESRD receiving HD have evidence
of extensive oxidation of lipids, thiols, proteins, and nucleic
acids and methylation of arginine that could contribute to
CVD. Many of these changes can be reduced by short-term
treatment with amlodipine and valsartan.
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Cardiovascular disease (CVD) accounts for over 50% of the
annual mortality of patients with end-stage renal disease
(ESRD) on maintenance dialysis.1 The prevalence of the
traditional cardiovascular risk factors, diabetes mellitus,
hypertension, smoking, and dyslipidemias, is high in this
patient population.2 However, the HEMO study concluded
that systolic blood pressure, smoking, or male gender were
not associated with an increased risk of CVD, whereas
diastolic blood pressure was actually inversely related.3
Hypercholesterolemia was associated with an increased
risk of coronary artery disease but not cerebrovascular
or peripheral vascular disease. More recently, a controlled
trial of lipid lowering with atorvastatin in hypercholestero-
lemic diabetic patients on hemodialysis (HD) reported
no beneficial effect on cardiovascular events.4 These
findings have prompted an interest in nontraditional risk
factors to explain the epidemiology of CVD in ESRD
population. These risk factors include oxidative stress,5
abnormal calcium and phosphate metabolism,6 hyperhomo-
cysteinemia,7 malnutrition and inflammation syndrome, and
the accumulation of the nitric oxide synthase inhibitor,
asymmetric dimethylarginine (ADMA).8 ADMA is an
independent predictor of endothelial dysfunction and CVD
both in patients with ESRD and the general population.
It is associated with a three-fold increased risk of future
severe cardiovascular events and mortality in patients on
HD9 and a four-fold increased risk of acute coronary events
in clinically healthy, nonsmoking men.10 In patients with
chronic kidney disease, ADMA is a strong predictor of
progression of chronic kidney disease and mortality.11,12
Therefore, it represents a novel therapeutic target for clinical
interventions. The pathogenesis of elevated ADMA levels is
not understood in patients with ESRD. Data from experi-
mental models suggest that oxidative stress increases the
activity of protein arginine methyltransferases (PRMTs)13
which methylate arginine moieties on proteins and inhibits
NG, NG-dimethylarginine-dimethylaminohydrolase (DDAH)
activity14 which specifically metabolizes ADMA. However,
effects of oxidative stress reduction on elevated plasma
levels of methylarginines in chronic kidney disease are not
known.
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Oxidative stress is the outcome of complex interactions
between oxidants and antioxidant defense pathways that
damage thiols, lipids, proteins, and nucleic acids. Although
the presence of oxidative stress is well documented in patients
with chronic kidney disease,15,16 there is currently no
consensus on a single ideal marker of oxidative stress.
Furthermore, effects of antihypertensive therapy on oxidative
stress have not been studied prospectively in ESRD patients.
Oxidation products of lipids, proteins, thiols, and DNA are
the most commonly measured parameters in clinical
studies.15–19 13-Hydroxyoctadecadienoic acid (13-HODE) is
a linoleic acid peroxidation product generated by the action
of 15-lipoxygenase and by non-enzymatic oxidation. It is a
stable parameter of lipid peroxidation that has been
implicated in the pathogenesis of atherosclerosis.20 Although
two trials of antioxidants reported a reduction in CVD events
in HD patients, these trials did not measure the markers of
oxidative stress or inflammation, thereby making their
interpretation somewhat uncertain.21,22
Treatment of HD patients with antagonists of renin–
angiotensin system reduces oxidative stress in observational
studies.23 Angiotensin II acting on AT1 receptors increases
superoxide generation in part by activating nicotinamide
adenine dinucleotide phosphate oxidase.24 The dihydro-
pyridine calcium channel blocker (CCB) amlodipine exerts
strong antioxidant actions in vitro in lipid-laden cell
membranes independent of its CCB action,25 but the
relevance of this to treatment of oxidative stress in vivo has
not been studied in ESRD patients. Although the antagonists
of the renin-angiotensin system and CCBs are the most
widely prescribed antihypertensive agents in patients on
maintenance HD,26 their antioxidant properties have not
been prospectively studied. Furthermore, the effects of these
antioxidant agents on methylarginine metabolism have not
been explored in this population. Therefore, we hypothesized
that in stable ESRD patients on maintenance HD, valsartan
(an angiotensin receptor blocker) and amlodipine (a CCB)
will lower oxidative stress, and that this will be associated
with a reduction in the plasma levels of ADMA independent
of blood pressure lowering. This was investigated in a double-
blind crossover trial of equally antihypertensive therapy with
these two agents.
RESULTS
A total of 30 patients were enrolled. Twenty-three
patients completed the study; seven patients withdrew
from the study owing to consent withdrawal (three),
transfer to another facility (one), and hospitalization
unrelated to the study (three). Four patients were excluded
from the final analysis owing to administration of intra-
venous iron during one of the study phases. This left 19
patients who comprised the study population. They were
matched with an equal number of healthy controls. The
baseline characteristics of the patients and the controls are
shown in Tables 1 and 2. There were no current smokers in
either group. The maximum dose of valsartan (320 mg daily)
and amlodipine (10 mg daily) was achieved in all study
subjects.
After 6 weeks of therapy, both amlodipine and valsartan
lowered 13-HODE by 29.7 and 14.4% (P¼ 0.09 for
valsartan), 8-hydroxy 2-deoxyguanosine by 21 and 19.5%,
ADMA by 38.1 and 39.2%, SDMA by 41.6 and 37.5%, and
GSSG:GSH by 40 and 79%, respectively (Table 3). Neither
treatment had any significant effect on plasma protein
carbonyl content, high-sensitivity C-reactive protein, or
L-arginine. A total of 10 patients received valsartan first and
nine patients received amlodipine first. Data were also
analyzed according to the order in which the study drugs
were administered and we detected no carry-over effect.
Additional antihypertensive drugs were used in all three
phases of the study to maintain the target blood pressure
level. During the amlodipine and valsartan phases, the drugs
used in the run-in period were withdrawn as required to
maintain a stable target BP, whereas the study drugs were
titrated up to full dose. Drugs used in the run-in, amlodipine,
and valsartan phases of the study were as follows: clonidine in
Table 1 | Patient characteristics
Variable
Patients
(n=19)
Controls
(n=19) P-value
Age (years) 57.9727 46.576 0.07
—
Gender F=12 F=14 —
M=8 M=6 —
Time on dialysis (months) 46731 — —
Etiology of ESRD
Hypertension 12 — —
Diabetes mellitus 4 — —
HIV-AN 2 — —
Lupus nephritis 1 — —
Unknown 1 — —
AN, associated nephropathy; ESRD, end-stage renal disease; F, female; HIV, human
immunodeficiency virus; M, male.
Table 2 | Biomarkers of oxidative stress and L-arginine
metabolism in patients with ESRD on maintenance HD
and healthy controls
Parameter
Controls
(n=19)
ESRD patients
(n=19) P-value
Plasma
13-HODE (nmol/ml) 210.4715.9 428.3726.8 o0.0001
Protein carbonyl (ng/mg) 0.0770.01 0.1770.01 o0.0001
8-HO2dG (ng/ml) 1.8870.14 2.8570.22 0.0013
HS-CRP (mg/l) 0.0770.008 0.8470.36 0.034
L-arginine (mmol/l) 95.373.2 86.774.8 0.15
ADMA (mmol/l) 0.5970.03 1.9470.12 o0.0001
SDMA (mmol/l) 0.6570.04 3.270.3 o0.0001
Whole blood
GSSG:GSH ( 100) 1.2370.54 2.971.2 0.04
ADMA, asymmetric dimethylarginine; ESRD, end-stage renal disease; GSH,
glutathione; HD, hemodialysis; 13-HODE, 13-hydroxyoctadecadienoic acid; 8-HO2dG,
8-hydroxy 2-deoxyguanosine; HS-CRP, high-sensitivity C-reactive protein; SDMA,
symmetric dimethylarginine.
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four, two, and two patients, labetalol in 12, 12, and 10
patients, and doxazosin in one, one, and one patient,
respectively and were not statistically different. Blood
pressure measured before HD three times a week was strictly
similar during the run-in and intervention phases (Figure 1).
Sixteen patients completed the 44-h ambulatory blood
pressure monitoring. This confirmed that there was no
difference in systolic (13975.9 vs 13775.9 mmHg), diastolic
(8073.7 vs 77.673.0 mmHg), or mean arterial pressure
(10273.8 vs 99.373.4 mmHg) between amlodipine and
valsartan therapy, respectively (Figure 2).
DISCUSSION
We confirmed previous reports of oxidative stress and
elevated plasma levels of ADMA and SDMA in patients with
ESRD.15–19 We detected widespread oxidation of all major
biomolecules (lipids, protein, thiols, and DNA). The main
new finding is that equi-antihypertensive therapy with
amlodipine and valsartan led to significant reductions in
many parameters of oxidative stress, and in plasma levels of
ADMA and SDMA.
We report 13-HODE as a new marker of lipid peroxida-
tion in this patient population. High levels of 13-HODE
cholesterol esters are found in atherosclerotic plaques in
humans atheromas20 where it may have a pathogenetic role.
Linoleic acid is the most abundant polyunsaturated fatty acid
in phospholipids including low-density lipoprotein, where its
abundance is about seven times that of arachidonic acid.27
Furthermore, it is the predominantly oxidized polyunsatu-
rated fatty acid in phospholipids.28 Oxidation of phospho-
lipids is an early event in the pathogenesis of atherosclerosis.
Once oxidized, phospholipids are recognized by the CD36
scavenger receptors on macrophages and smooth muscle
cells29 and their uptake by these cells results in the formation
of foam cells. Low concentrations of oxidized phospholipids
stimulate the proliferation of smooth muscle cells and
high concentrations increase ceramide and smooth muscle
cell apoptosis30 and release cytochrome c from the mito-
chondria.31 These events may contribute to the formation of
a necrotic core in the plaque. Thus, oxidized phospholipids
are involved in several steps of atherogenesis. Endothelial cells
also synthesize 9- and 13-HODE.32 We found that amlo-
dipine was more effective in lowering plasma levels of
Table 3 | Effects of therapy with amlodipine and valsartan on parameters of oxidative stress and methylarginines in 19
patients on HD
Parameter Baseline Amlodipine Valsartan P-value (ANOVA)
Plasma
13-HODE (nmol/ml) 428.3726.8 301.0714.0* 366.8715.8 0.002
Protein carbonyl (ng/mg) 0.1770.01 0.1670.01 0.1770.01 0.81
8-HO2dG (ng/ml) 2.9770.22 2.3470.2* 2.3970.15* 0.028
HS-CRP (mg/l) 0.8470.36 1.470.92 1.3370.5 0.83
L-arginine (mmol/l) 86.774.8 78.274.8 79.375.5 0.4
ADMA (mmol/l) 1.9470.12 1.270.16* 1.1870.1* o0.0001
SDMA (mmol/l) 3.270.3 1.8770.24* 2.070.23* 0.001
Whole blood
GSSG:GSH ( 100) 2.973.1 1.871.3* 0.670.1* 0.02
ADMA, asymmetric dimethylarginine; ANOVA, analysis of variance; GSH, glutathione; HD, hemodialysis; 13-HODE, 13-hydroxyoctadecadienoic acid; 8-HO2dG, 8-hydroxy
2-deoxyguanosine; HS-CRP, high-sensitivity C-reactive protein; SDMA, symmetric dimethylarginine.
*Significant at Po0.05.
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Figure 1 | Results of in-center pre-HD blood pressure. (sys, systolic;
dia, diastolic; aml, amlodipine; val, valsartan).
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Figure 2 | Results of 44-h interdialytic ambulatory blood pressure
monitoring. (aml, amlodipine; val, valsartan).
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13-HODE than valsartan. Amlodipine is highly lipophilic and
accumulates in cell membranes, where it can inhibit lipid
peroxidation independent of its action as CCB.25 Within the
phospholipid bilayer of the cell membrane, the charged
amino pole of amlodipine is positioned next to the
oppositely charged groups whereas the hydrophobic pole is
buried in the membrane hydrocarbon core, thereby aligning
the dihydropyridine conjugated ring with phospholipid acyl
chains which are an important target for peroxidation.
Amlodipine scavenges free oxygen radicals by donating two
abstractable hydrogen atoms associated with its aromatic
ring, thereby breaking the lipid peroxidation chain reaction.33
Evidence of an in vivo antioxidant action of amlodipine on
lipids was provided by an approximately 30% reduction in
the plasma levels of 13-HODE in our study.
The evidence of lipid oxidation in patients on HD was
accompanied by evidence of oxidation of thiols, proteins, and
nucleic acids. GSH is an important intracellular antioxidant
that modulates vascular tone by scavenging free oxygen
radicals. Intracoronary administration of GSH in high-risk
individuals improves coronary endothelial vasomotor func-
tion.34 We confirmed an increased oxidation of GSH in ESRD
patients. We found a significant reduction in the oxidized
fraction of GSH with valsartan and amlodipine, which
indicates an improvement in the redox milieu. A similar
reduction in GSH oxidation is also seen in patients with
essential hypertension treated with candesartan and amlo-
dipine.35 Neither treatment had an effect on elevated plasma
levels of high-sensitivity C-reactive protein, or protein
carbonyl. The relatively short duration of our study may
explain the lack of a reduction in these parameters. We
limited the duration of each study arm to 6 weeks to avoid
the high drop-out rate owing to concurrent illnesses and
requirement for intravenous iron in this population, which
could confound the oxidative stress parameters.36 Compart-
mentalization of the oxidative processes within the cells may
also explain some of the differences in the oxidative stress
parameters and may limit the ability of these drugs to exert
antioxidant effects.
We confirmed the reports of increased plasma levels of
ADMA and SDMA, with unchanged L-arginine, in HD
patients.8 However, a new finding was the marked reduction
in the plasma levels of these methylarginines during
treatment with amlodipine and valsartan. Methylarginines
result form methylation of the arginine residues in proteins
by PRMTs using s-adenosylmethionine as a methyl donor.37
Upon hydrolysis of the proteins, free methylarginines appear
in the cytosol. The asymmetrically methylated arginines
(ADMA and N-monomethyl-L-arginine), but not SDMA,
inhibit nitric oxide synthase. ADMA, in addition, upregulates
the expression of lectin-like OxLDL receptor in cultured
human monocytes, leading to a 2.4-fold increase in the
intracellular concentration of OxLDL.38 DDAH hydrolyses
ADMA to citrulline and dimethylamine which is its major
route of its elimination, whereas SDMA is eliminated
principally by renal excretion.39 The absence of renal
excretion accounts for the higher plasma levels of SDMA
than ADMA in patients with ESRD. Both isoforms of DDAH
(1 and 2) are inhibited by oxidation and nitrosation.14 In this
study, both amlodipine and valsartan were effective in
lowering ADMA levels which might therefore be secondary
to a reduction in oxidative inactivation of DDAH. However, a
reduced inactivation of DDAH would not be expected to
yield the parallel reduction in plasma SDMA levels. Rather,
the finding of an equivalent and parallel reduction in both
methylarginines by these drugs suggests a reduction in the
activity of PRMTs, which may be redox-sensitive. Indeed, the
gene expression of PRMTs in cultured endothelial cells is
increased by native and oxidized low-density lipoprotein
which can be blocked by the antioxidant pyrrolidine
dithiocarbamate.13 In a dog model of chronic renal failure,
the plasma levels of ADMA can be lowered by inhibiting
PRMT with adenosine dialdehyde.40 This suggests that both
amlodipine and valsartan may lower ADMA and SDMA by
limiting the activity of PRMTs and this may be secondary to
their antioxidant properties. Additionally, a reduction in the
endothelial shear stress by these agents could also lower
the oxidative stress and plasma ADMA levels. A mild-
to-moderate degree of shear stress increases the release of
ADMA from the human umbilical vein endothelial cells by
upregulating PRMT-I expression.41 This effect is mediated by
the activation of nuclear factor-kB pathway and involves
upregulation of redox-sensitive genes encoding endothelial
adhesion molecules. On the other hand, shear stress at a
higher magnitude reduces the ADMA release to the baseline
by increasing DDAH activity. Therefore, therapy with
antihypertensive agents may lower plasma ADMA levels in
part by reducing shear stress. In fact, 1-week therapy with
enalapril, eprosartan, and a combination of these agents
lowered the plasma ADMA levels in essential hypertension by
16.5, 15.9, and 18%, respectively42 for a similar blood
pressure, except the combination phase in which the mean
blood pressure was lower than the other phases. However,
plasma SDMA and parameters of oxidative stress were not
measured in this study. In another study in patients with
essential hypertension, perindopril, losartan, and bisoprolol
decreased blood pressure to a similar extent, but only
perindopril and losartan, lowered the plasma ADMA levels,
whereas bisoprolol had no such effect.43 Findings from these
studies suggest a beneficial effect of the antagonists of the
renin–angiotensin system on plasma ADMA levels which
appears to be independent of their blood pressure-lowering
properties. However, in patients with type II diabetes and
normal renal function, therapy with olmesartan lowered
blood pressure, renal vascular resistance, 15(S)-8-iso-prosta-
glandin F2a (a marker of lipid peroxidation) and improved
renal plasma flow without lowering the plasma ADMA
levels.44 In our study, we could not entirely attribute the
beneficial effects of valsartan and amlodipine on oxidative
stress and methylarginine to blood pressure lowering alone,
as the degree of blood pressure control was exactly similar in
the run-in and intervention phases.
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In summary, we report high plasma levels of methylargi-
nines and oxidation of proteins, lipids, thiols, and DNA in
patients with ESRD on HD. Therapy with amlodipine and/or
valsartan lowered ADMA and SMDA levels equally indepen-
dent of blood pressure lowering and both effectively reduced,
but did not normalize parameters of oxidative stress. These
findings point to the need for clinical trial of these agents to
determine if this reduction in oxidative stress and arginine
methylation translates into an improvement in the cardio-
vascular end points in patients with ESRD.
MATERIALS AND METHODS
Study design
This was a randomized, double-blind crossover study conducted on
stable patients on maintenance HD between November 2002 and
August 2004 at Georgetown University Hospital affiliated dialysis
facilities. The study protocol was approved by the Institutional
Review Boards of Georgetown University and the respective dialysis
units. Patients aged 18 years or above established on regular three
times weekly maintenance HD for at least 3 months with single-pool
Kt/V of 41.2 who required antihypertensive therapy were eligible to
participate. The exclusion criteria were: patients with active
infection, malignancy, absolute requirement for antagonists of the
renin–angiotensin system or CCBs, use of antioxidant or herbal
medications, predialysis serum potassium (SK) concentration of
45.0 mEq/l within the previous 3 months, a history of an adverse
reaction to valsartan or amlodipine, and hematocrit o32%.
Informed consent was obtained from the study participants. After
enrollment, there was a 2-week run-in period during which
angiotensin converting enzyme inhibitors, angiotensin receptor
blockers, or CCBs were withdrawn from the patients receiving these
agents and substituted with labetalol, clonidine, or doxazosin to
achieve a predialysis blood pressure of o150/90 mmHg. This level
was selected as it was an achievable target BP in this patient
population. Blood for the baseline labs was drawn at the end
of this run-in period before the start of HD and heparin
administration. Patients were then randomized to therapy
with either valsartan 160 mg daily or amlodipine 5 mg daily in
a double-blind manner for 6 weeks. A computer-generated
block-randomization method was used to establish the order
of therapy for each subject. During each intervention phase, the
dose of valsartan or amlodipine was titrated to a maximum of 320
or 10 mg daily, respectively. The antihypertensive agents used
during the run-in period were withdrawn as needed to achieve
an equivalent pre-HD blood pressure control of o150/90 mmHg.
At the end of 6 weeks, each patient had an ambulatory blood
pressure monitoring performed for 44 h of interdialytic period
to confirm equivalent blood pressure control. The predialysis
blood sample for the second set of labs was drawn at the conclusion
of this 6-week period. This was followed by a 2-week washout
period during which the study drug was discontinued and the
doses of other antihypertensive agents were titrated as needed in the
same manner as during the run-in phase. Patients were then
treated with the second study drug for 6 weeks with the same
blood pressure goal. A second 44-h ambulatory blood pressure
monitoring preceded the last set of lab draws, which concluded
the study.
Patients were excluded from the final analysis if they (1) required
intravenous iron, (2) had an infection that required treatment with
antibiotics, (3) had a hospitalization, or (4) had a predialysis
SK elevation to 46 mEq/l, or (5) had a Kt/V o1.2. A group of
healthy age- and sex-matched volunteers who were taking no
medications served as control.
Sample collection and handling
Blood for the biochemical analyses was drawn in the dialysis facility
into pre-chilled vacutainers containing either heparin or ethylene-
diaminetetraacetic acid before initiation of a midweek dialysis
session before heparin administration. The samples were imme-
diately centrifuged at 41C, aliquoted, frozen, and transported on dry
ice. They were stored at 801C until the analyses. All biochemical
analyses were performed in two batches with a known concentration
of internal controls. All samples were run in triplicates.
Biochemical analyses
Plasma ADMA, SDMA, and L-arginine were measured by high-
performance liquid chromatography. Samples were diluted and
applied to a preconditioned chlorobenzoic acid (CBA) solid-phase
extraction cartridge. After elution with methanol:ammonia, the
dried extracts were derivatized and injected onto a C18 high-
performance liquid chromatography column (25 4.6 mm). ADMA
and SDMA were quantified by reference to their fluorescence
emissions. Data were acquired onto a HP Chemstations and peak
areas determined. The intra- and inter-assay coefficients of
variability (CVs) were 3.1 and 3.6%, respectively for plasma ADMA
and 2.6 and 3.1% for plasma SDMA.
Plasma 13-HODE was measured by high-performance liquid
chromatography. Plasma was acidified with acetic acid to pH of 3
and extracted with hexane-isopropanol. After degassing, the samples
were vortexed for 30 s. After centrifugation, the organic layer was
transferred to a clean vial and evaporated under nitrogen. Samples
were reconstituted with 100 ml of methanol and diluted 1/1 with
mobile phase. Fifty microlitres was injected onto the high-
performance liquid chromatography (25 4.6 mm column- Spher-
isorb C18). The mobile phase consisted of 25 mM sodium sulphate
and methanol (40/60) at 1.25 ml/min. Quantification was achieved
through integration of areas using Chemstations. Peaks were
monitored by ultraviolet at 236 nm (72 nm) with a 400 nm
(750 nm) background subtract. The intra- and inter-assay CVs
were 3.2 and 4.1%, respectively.
Serum high-sensitivity C-reactive protein was measured by
nephelometry (Dade Behring Inc., Deerfield, IL, USA). The intra-
and inter-assay CVs were 3.8 and 5.0%, respectively. Whole-blood
reduced (GSH) and oxidized glutathione (GSSG) and GSSG/GSH
ratio were measured using a method (Oxisresearch, Portland, OR,
USA) that uses 5,50-dithiobis-2-nitrobenzoic acid as described by
Tietze.45 1-Methyl-2-vinylpyridinium trifluoromethanesulfonate
was added to freshly drawn whole blood to scavenge GSH for
GSSG measurement. The whole-blood GSH assay had intra- and
inter-assay CVs of 3.6 and 8.4%, respectively. The whole-blood
GSSG assay had intra- and inter-assay CVs of 6.4 and 9.6%,
respectively.
Plasma levels of protein carbonyl were measured by an enzyme-
linked immunosorbent assay (ZenTech, Dunedin, New Zealand)
with the method of Buss et al.46 Briefly, samples containing protein
are reacted with dinitrophenylhydrazine. The protein is nonspeci-
fically adsorbed to an enzyme-linked immunosorbent assay plate.
Unconjugated dinitrophenylhydrazine and non-protein constituents
are washed away. The adsorbed protein is probed with biotinylated
anti-dinitrophenylhydrazine antibody followed by streptavidin-
linked horseradish peroxidase. Serum albumin containing increasing
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proportions of hypochlorous acid is used as standard curve. Intra-
and inter-assay CVs were 7.5 and 12.5%, respectively.
Plasma 8-hydroxy 2-deoxyguanosine was measured by enzyme-
linked immunosorbent assay.47 A monoclonal immunoglobulin G
(N45.1) specific for 8-hydroxy 2-deoxyguanosine was used in this
enzyme-linked immunosorbent assay in combination with horse-
radish peroxidase-conjugated anti-mouse polyclonal immuno-
globulin G and substrate o-phenylenediamine. Plasma was filtered
using Millipore Ultrafilterss (Billerica, MA, USA), with 10 000
dalton molecular weight cutoff before the assay. The intra- and
inter-assay CVs were 4.6 and 6.2%, respectively.
Data analysis
All values are expressed as mean7s.e.m. All parameters were tested
for normal distribution using Kolmogorov–Smirnov test and log-
transformed if not normally distributed. An unpaired Student’s
t-test was used to compare values between HD patients and healthy
controls. Repeated-measures analysis of analysis of variance was
used to compare the effects of both treatments with the baseline
values. A paired t-test was used to compare the effects of treatment
among both interventions and the baseline. Wilcoxon-matched pairs
test was used to compare groups when data were not normally
distributed. A P-valueo0.05 was considered statistically significant.
To eliminate carry-over effect, the data were further analyzed
according to the order in which the study drugs were administered.
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